EVALUATING THE EFFECT OF SPARSENTAN VS IRBESARTAN ON URINE INFLAMMATORY AND PROFIBROTIC BIOMARKERS IN THE PHASE 3 PROTECT TRIAL OF PATIENTS WITH IMMUNOGLOBULIN A NEPHROPATHY